You have 9 free searches left this month | for more free features.

BRVO

Showing 1 - 25 of 78

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Branch Retinal Vein Occlusion, Retinal Blood Flow, Retinal Oxygen Saturation Trial in Vienna (Dynamic Vessel Analyzer,

Recruiting
  • Branch Retinal Vein Occlusion
  • +2 more
  • Dynamic Vessel Analyzer
  • Bidirectional Fourier-Domain Optical Coherence Tomography (FDOCT)
  • Vienna, Austria
    Department of Clinical Pharmacology, Medical University of Vienn
Apr 6, 2022

Branch Retinal Vein Occlusion, Ranibizumab, Laser Photocoagulation Trial in Beijing (Ranibizumab combined macular laser,

Completed
  • Branch Retinal Vein Occlusion
  • +2 more
  • Beijing, Beijing, China
    Beijing Hospital
Dec 25, 2022

Branch Retinal Vein Occlusion Trial in BeiJing (601 1.25mg, Ranibizuman 0.5 mg)

Not yet recruiting
  • Branch Retinal Vein Occlusion
  • 601 1.25mg
  • Ranibizuman 0.5 mg
  • BeiJing, Beijing, China
    BeiJing Hospital
Dec 8, 2020

Use of Aflibercept Injections Into Eye for Treatment of Eye

Recruiting
  • Retinal Disease
  • Aflibercept (BAY86-5321, Eylea)
  • Multiple Locations, Mexico
    Many locations
Aug 22, 2022

Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration Trial in Springfield,

Active, not recruiting
  • Age-Related Macular Degeneration
  • +4 more
  • bevacizumab
  • Springfield, Illinois
  • +2 more
Dec 6, 2021

Branch Retinal Vein Occlusion Trial in Shenyang (Bevacizumab Ophthalmic and Intravitreal Dexamethasone, Bevacizumab Ophthalmic)

Unknown status
  • Branch Retinal Vein Occlusion
  • Bevacizumab Ophthalmic and Intravitreal Dexamethasone
  • Bevacizumab Ophthalmic
  • Shenyang, Liaoning, China
    He Eye Specialist Hospital
Oct 20, 2020

Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration Trial in United States

Completed
  • Age-related Macular Degeneration
  • +4 more
  • bevacizumab
  • Tucson, Arizona
  • +19 more
Nov 16, 2021

Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO) Trial in Japan (Ranibizumab, Grid&Direct short pulse laser

Completed
  • Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
  • Ranibizumab
  • Grid&Direct short pulse laser photocoagulation
  • Nagakute-city, Aichi, Japan
  • +6 more
Feb 11, 2020

Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion Trial in Palo Alto (nicotinic acid)

Terminated
  • Central Retinal Vein Occlusion
  • Branch Retinal Vein Occlusion
  • nicotinic acid
  • Palo Alto, California
    Palo Alto Medical Foundation Department of Ophthalmology
Oct 21, 2019

Branch Retinal Vein Occlusion, Macular Edema Trial in Odense, Roskilde (Aflibercept Injection [Eylea], Navigated laser

Completed
  • Branch Retinal Vein Occlusion
  • Macular Edema
  • Aflibercept Injection [Eylea]
  • Navigated laser photocoagulation
  • Odense, Danmark, Denmark
  • +1 more
Apr 18, 2022

Branch Retinal Vein Occlusion With Macular Edema Trial in Daegu (Intravitreal bevacizumab and dexamethasone implant Injection,

Unknown status
  • Branch Retinal Vein Occlusion With Macular Edema
  • Intravitreal bevacizumab and dexamethasone implant Injection
  • Intravitreal dexamethasone implant
  • Daegu, Korea, Republic of
    Yeungnam university hospital
Mar 26, 2019

Macular Edema, Retinal Vein Occlusion Trial in Assiut (Intravitreal injection of Dexamethasone implant)

Recruiting
  • Macular Edema
  • Retinal Vein Occlusion
  • Intravitreal injection of Dexamethasone implant
  • Assiut, Egypt
    Faculty of medicine
Feb 27, 2022

Retinal Vein Occlusion, Macula Edema Trial in United States (TLC399 (ProDex))

Completed
  • Retinal Vein Occlusion
  • Macula Edema
  • TLC399 (ProDex)
  • Phoenix, Arizona
  • +19 more
Nov 24, 2021

Branch Retinal Vein Occlusion Trial in Leipzig (Ranibizumab)

Completed
  • Branch Retinal Vein Occlusion
  • Leipzig, Germany
    Department of Ophthalmology, University Leipzig
Nov 30, 2018

Anti-VEGF, Branch Retinal Vein Occlusion, Vitrectomy Trial (anti-VEGF, fan-shaped photocoagulation)

Unknown status
  • Anti-VEGF
  • +2 more
  • anti-VEGF
  • fan-shaped photocoagulation
  • (no location specified)
Aug 16, 2018

Branch Retinal Vein Occlusion Trial in Worldwide (Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection)

Terminated
  • Branch Retinal Vein Occlusion
  • Brolucizumab 6 mg
  • +2 more
  • Phoenix, Arizona
  • +101 more
Jan 27, 2023

Branch Retinal Vein Occlusion With Macular Edema Trial in Stockholm (Aflibercept Injection [Eylea], Ranibizumab Injection

Recruiting
  • Branch Retinal Vein Occlusion With Macular Edema
  • Aflibercept Injection [Eylea]
  • Ranibizumab Injection [Lucentis]
  • Stockholm, Sweden
    St Eriks Eye Hospital
Dec 2, 2020

Macular Edema, Branch Retinal Vein Occlusion Trial in Worldwide (Faricimab, Aflibercept, Sham Procedure)

Active, not recruiting
  • Macular Edema
  • Branch Retinal Vein Occlusion
  • Phoenix, Arizona
  • +151 more
Aug 4, 2022

Retinal Vein Occlusion Trial in Palo Alto (Nicotinic acid, Prednisolone acetate)

Completed
  • Retinal Vein Occlusion
  • Nicotinic acid
  • Prednisolone acetate
  • Palo Alto, California
    Palo Alto Medical Foundation Department of Ophthalmology
Dec 18, 2018

Retinal Vein Occlusion Trial in Bethesda, Bristol (Minocycline, Placebo, Bevacizumab)

Completed
  • Retinal Vein Occlusion
  • Bethesda, Maryland
  • +1 more
Dec 27, 2021

Macular Degeneration, Wet, Metamorphopsia Trial

Recruiting
  • Macular Degeneration, Wet
  • Metamorphopsia
    • Cuneo, Piedmont, Italy
      Ospedale Santa Croce
    Sep 20, 2022

    Central Retinal Vein Occlusion With Macular Edema, Branch Retinal Vein Occlusion With Macular Edema Trial in Taiwan (TLC399)

    Completed
    • Central Retinal Vein Occlusion With Macular Edema
    • Branch Retinal Vein Occlusion With Macular Edema
    • Chang Hua, Taiwan
    • +5 more
    Nov 24, 2021

    Macular Edema, Retinal Vein Occlusion Trial in Worldwide (KSI-301, Aflibercept, Sham Procedure)

    Active, not recruiting
    • Macular Edema
    • Retinal Vein Occlusion
    • Phoenix, Arizona
    • +140 more
    Jul 20, 2022

    Central Retinal Vein Occlusion Trial in TianJing (601 1.25mg, Ranibizuman 0.5 mg)

    Not yet recruiting
    • Central Retinal Vein Occlusion
    • 601 1.25mg
    • Ranibizuman 0.5 mg
    • TianJing, TianJing, China
      TianJing Medical University Eye Hospital
    Dec 8, 2020

    Study for Collection of Aflibercept Data in Routine Practice

    Completed
    • Eye Diseases
    • Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
    • Multiple Locations, France
      (unnamed)
    Jul 1, 2019